Wearable Injectors and Connected Devices Conference 2019

SMi Group9 - 10 October 2019, London, UK.
SMi is proud to present the inaugural Wearable Injectors and Connected Devices Conference, taking place in London. The global wearable devices market size is expected to reach a value of $12.1 billion USD by 2021 with time dependent delivery, large volume administration with minimal injection pain and the use of connectivity to enhance user-value being key factors driving the market.

With this in mind, the conference will explore new technologies and advances of on-body devices for the administration of viscous and large molecule drug delivery, and evaluate the impact of IoT, connectivity and enhancement of user-interface, which make up core components within the wearable devices field.

Benefits of Attending

  • Listen to case studies from leading pharmaceutical companies revolutionising the medical device industry
  • Hear how on-body injectors are facilitating the administration of time-dependent, large volume and viscous drug delivery
  • Assess how connectivity is being used to improve patient adherence, health-monitoring and enhancing the user-interface
  • Explore the compatibility, pain and patient handling considerations projecting wearable devices as the future of drug delivery

Join Wearable Injectors and Connected Devices Conference 2019 in October 2019 to have the opportunity to network with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Plus two interactive pre-conference workshops

Tuesday 8th October 2019

Cross company collaboration to develop digital therapeutic solutions using connected devices

Workshop Leader: Digby Harris, Global Category Manager - Digital Therapeutics & Devices, AstraZeneca

Wearable injectors: Envisioning their evolution to address current and future unmet needs

Workshop Leader: James Blakemore, Senior Consultant, Cambridge Consultants
Workshop Leader: Sergio Marlorni, Senior Consultant, Cambridge Consultants

Who should attend?

Executives, Directors, VPs, Heads, Principals, Managers of: Drug-delivery developers, Autoinjectors, Device Engineering, Human Factor, Scientist, Product, Injectables, Packaging, Regulatory Affairs, Connectivity, Medical Device Data, Novel Product Technology, Smart device developers, Training device developers, Device-safety solution providers, Drug developers or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceutical, biotech and solution providers.

To register please visit: www.wearable-injectors.co.uk/wpnwl

Early-Bird Rates

  • Book by 31st May and save £400
  • Book by 28th June and save £300
  • Book by 30th August and save £200

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...